Biotech Values

[DewDiligence]

EGRX regulatory scorecard:

• FDA approval of Bendeka on 12/8/13 (#msg-119003236);

• FDA approval of alcohol-free Docetaxel today (#msg-119399276);

• PDUFA date for liquid Angiomax on 3/19/16 (#msg-118876127, #msg-118484166);

• Guaranteed US launch date for “big bag” Bendamustine on 5/1/16 (#msg-118558328);

• Meeting with FDA to discuss phase-2 Ryanodex data in EHS (#msg-119245128).

All told, that’s a lot of activity for a relatively small company.

Thanks mainly to Bendeka (#msg-119003236), EGRX will soon be a cash-generation machine—i.e. the kind of acquisition that would be immediately and strongly accretive to EPS for any of the major generic-drug players.